Explaining the high rate of progression from prediabetes to type 2 diabetes in China
- PMID: 37884324
- DOI: 10.1016/S2213-8587(23)00282-6
Explaining the high rate of progression from prediabetes to type 2 diabetes in China
Conflict of interest statement
EC and JC have received institutional research support from Merck KGaA. JC has received speakers' fees from Merck KGaA. All other authors declare no competing interests.
Comment in
-
Explaining the high rate of progression from prediabetes to type 2 diabetes in China - Authors' reply.Lancet Diabetes Endocrinol. 2023 Nov;11(11):794-795. doi: 10.1016/S2213-8587(23)00283-8. Lancet Diabetes Endocrinol. 2023. PMID: 37884323 No abstract available.
Comment on
-
Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.Lancet Diabetes Endocrinol. 2023 Aug;11(8):567-577. doi: 10.1016/S2213-8587(23)00132-8. Epub 2023 Jul 3. Lancet Diabetes Endocrinol. 2023. PMID: 37414069 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
